Somewhat Positive Media Coverage Somewhat Unlikely to Impact Novartis AG (NVS) Share Price
Headlines about Novartis AG (NYSE:NVS) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novartis AG earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.678029464502 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s analysis:
- Novartis: Alcon Gets European CE Mark For Clareon IOL With AutonoMe (nasdaq.com)
- Novartis AG’s (NVS) Hold Rating Affirmed (investorplace.com)
- FY2018 EPS Estimates for Novartis AG Decreased by Jefferies Group (NVS) (americanbankingnews.com)
- Novartis AG (NVS) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Why Investors willing to pay more for Novartis AG (NVS) | Street … – Street Observer (press release) (streetobserver.com)
Novartis AG (NVS) traded up 0.15% during mid-day trading on Friday, reaching $85.77. The firm has a market cap of $200.95 billion, a PE ratio of 31.31 and a beta of 0.73. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The stock has a 50 day moving average price of $84.84 and a 200-day moving average price of $81.39.
Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company’s revenue was down 1.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.23 EPS. On average, equities analysts anticipate that Novartis AG will post $4.75 earnings per share for the current year.
A number of research analysts have recently weighed in on NVS shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Tuesday, September 5th. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company reiterated a “hold” rating on shares of Novartis AG in a report on Tuesday, July 18th. Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a report on Monday, July 10th. Finally, Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a report on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $85.12.
TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-novartis-ag-nvs-share-price/1618442.html.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.